Whether serputinib/serpatinib may be included in medical insurance in 2025

Selpercatinib is a highly selective RET tyrosine kinase inhibitor, mainly used to treat RET fusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer associated with RET mutations or fusions. Since its rapid approval by the US FDA in 2020, the drug has attracted much attention in the international tumor treatment field due to its precise molecular targeting mechanism and significant efficacy. Currently, seputinib has been approved by the China Food and Drug Administration for the treatment of patients with RET fusion-positive locally advanced or metastatic NSCLC, but it has not yet been officially included in the domestic medical insurance directory. Whether you can enter medical insurance in the future depends on many factors.

First of all, inclusion in medical insurance requires the National Medical Security Administration to conduct a systematic evaluation of the clinical value, economics, safety and population coverage of the drug. Seputinib showed excellent objective response rate (ORR) and long progression-free survival (PFS) in the large international clinical study LIBRETTO-001, showing high inhibitory specificity and clinical benefit against RET fusion mutation targets, so its efficacy advantages have been widely recognized. Secondly, the key to medical insurance negotiations also includes drug pricing and corporate profit margins. Currently, as an original imported targeted drug, Seputinib is relatively expensive. The market price of each box (40mg*60 tablets) may exceed 10,000 yuan.

In addition, considering that the population of RET fusion-positive NSCLC and RET mutant thyroid cancer is relatively small, its precision treatment characteristics are more in line with the current development trend of medical insurance cost control and targeted precision medicine. Once included in medical insurance, it will not only significantly reduce the financial burden on patients, but also promote the clinical application of more tumor molecular classifications. In summary, seputinib has strong potential to be included in medical insurance, but policy support and corporate cooperation are still needed to achieve the goal of benefiting a wide range of patients.

Reference:https://en.wikipedia.org/wiki/Selpercatinib